This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Lupus; antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)	Integrin α_2 (VLA-2; CD49B); notch homolog 1 translocation-associated (NOTCH1); protein tyrosine phosphatase non-receptor type 22 (PTPN22; LYP)	Genetic studies suggest that levels of ITGA2, NOTCH1 and PTPN22 on CD8 ⁺ T cells could help predict responsiveness to lupus and AAV therapies. Next steps include developing a prognostic to identify patients who will require higher immunosuppression for the treatment of relapsing-remitting autoimmune diseases. SciBX 3(17); doi:10.1038/scibx.2010.535 Published online April 29, 2010	International patent application filed by Cambridge Enterprise; available for licensing	McKinney, E. <i>et al. Nat. Med.</i> ; published online April 18, 2010; doi:10.1038/nm.2130 Contact: Kenneth G.C. Smith, University of Cambridge School of Clinical Medicine, Cambridge, U.K. e-mail: kgcs2@cam.ac.uk Contact: Paul A. Lyons, same affiliation as above e-mail: pal34@cam.ac.uk